# Proimmune, Inc.

Canonical: https://abierto.us/vendors/proimmune-inc-c97dj9nybgv9

- UEI: C97DJ9NYBGV9
- CAGE: 4V3U8
- Parent: Proimmune Inc.
- Location: Sarasota, FL
- Awards in window: 2 (2 transactions), -$5,267 obligated, July 29, 2026 to August 25, 2026

## Awarding agencies

- Food and Drug Administration: 1 awards, -$1
- National Institutes of Health: 1 awards, -$5,266

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): -$1
- 541990 All Other Professional, Scientific, and Technical Services: -$5,266

## Competition

- Competed Under SAP: 1 awards
- Not Competed Under SAP: 1 awards

## Largest awards

- 75F40121P00423 (purchase order): -$1, FDA Office of Acq Grant SVCS. The Purpose of This Modification Is to De-Obligate Excess Funds and Close Out the Contract.. https://www.usaspending.gov/award/CONT_AWD_75F40121P00423_7524_-NONE-_-NONE-/
- 75N93021P00656 (purchase order): -$5,266, National Institutes of Health Niaid. To Administrate De-Obligate Unexpended and Expiring Fiscal Year 2021 Funding in Accordance with 31 U.S.C. Section 1552 (A), in Preparation for September 30, 2026, Closing of the Period of Availability of These Fiscal Year Funds.. https://www.usaspending.gov/award/CONT_AWD_75N93021P00656_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/proimmune-inc-c97dj9nybgv9.